Related references
Note: Only part of the references are listed.Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
Luis H. Camacho
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Next generation of immunotherapy for melanoma
John M. Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer
N. Wallis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
Begona Comin-Anduix et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects
Scott E. Strome et al.
ONCOLOGIST (2007)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Chemotherapy for metastatic melanoma - Time for a change?
Helen J. Gogas et al.
CANCER (2007)
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma
A. D. Sasse et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Targeting Nodal in malignant melanoma cells
Lynne-Marie Postovit et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI-Mel.A.) [ISRCTN75125874]
V Chiarion-Sileni et al.
BMC CANCER (2006)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells
MS Kuhns et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
